The following is a summary of “Bimekizumab durability of efficacy through 196 weeks and safety through 4 years in patients ...

Healio spoke with Raj Chovatiya, MD, PhD, about results from the phase 3 ICONIC-LEAD trial presented at the 2025 Academy of ...

Studies involving multiple aspects of plaque psoriasis evolution, persistence, and progression have produced clues and ...

VYNE pauses VYN202 psoriasis trial after FDA clinical hold tied to animal toxicity data; separate vitiligo trial remains on ...

Oruka Therapeutics, Inc. (“Oruka”) (Nasdaq: ORKA), a clinical stage biotechnology company developing novel biologics designed ...

Managed Healthcare Executive gives C-suite executives in health plans and provider organizations news and strategies for ...

The hold, placed by the FDA on an early-stage clinical trial of an experimental BET inhibitor, stems from a recent ...

Art Garfunkel discusses his experience living with psoriasis as part of Sun Pharma’s I LUV YA for The Long Haul campaign.

Otulfi is FDA-approved for subcutaneous and intravenous formulations to treat the same conditions as Stelara (ustekinumab), ...

In February, VYNE Therapeutics dosed the first subject in a Phase 1b trial evaluating VYN202 in moderate-to-severe plaque psoriasis. The clinical hold does not apply to VYNE’s ongoing Phase 2b ...